Namibia

Reimbursed Care Access

Namibia maintains a restrictive national drug-control framework inherited from older legislation; most classical psychedelics (psilocybin, MDMA, DMT, mescaline, 5‑MeO‑DMT, 2C‑X, ibogaine, ayahuasca) are treated as prohibited/controlled substances with no authorized outpatient therapeutic programs. Ketamine is widely used and accepted within clinical practice as an anaesthetic and analgesic; its off‑label psychiatric use (and esketamine products) are not part of any known public reimbursement program and appear to require private/clinical arrangements or formal registration for market authorization. Regulatory oversight for medicines and registration in Namibia is performed by the Namibia Medicines Regulatory Council (NMRC) under the Medicines and Related Substances Control Act. [https://namiblii.org/akn/na/act/1971/41/eng%401986-01-01|NamibLII - Abuse of Dependence‑Producing Substances Act] [https://nmrc.gov.na/whoweare|Namibia Medicines Regulatory Council (NMRC)]